TAI · 1795.TW
Lotus Pharmaceutical Co., Ltd.
NT$167.50-NT$5.00 (-2.9%)
Lotus Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 54.67% below the high.
Loading market information…
TAI · 6472.TW · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Bora Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.78% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Bora Pharmaceuticals Co., Ltd.’s forward annual dividend is NT$10.00 per share, paid annual. The forward yield is 2.64% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Bora Pharmaceuticals Co., Ltd.’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of NT$5.21. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bora Pharmaceuticals Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Globally, Bora Pharmaceuticals Co., LTD. is engaged in the comprehensive lifecycle of pharmaceutical products, encompassing research and development, manufacturing, distribution, and sales. The organization operates through key divisions, including Sales, Contract Development & Manufacturing Organization (CDMO), and other ancillary services. Bora produces and markets a diverse range of medicines, from generic and proprietary brand-name drugs to over-the-counter (OTC) remedies. Beyond its in-house portfolio, the company provides extensive contract development and manufacturing solutions. These CDMO services cover all stages of pharmaceutical development, clinical and commercial production, specialized packaging and serialization, rigorous analytical and microbiological quality control, and expert guidance on regulatory compliance. Furthermore, Bora's offerings extend to nutritional supplements, skincare products, and various biotechnical services. The company distributes its goods directly to healthcare facilities such as clinics, pharmacies, and pharmacy chains, as well as to drugstores. It also leverages distributors to supply larger institutions like medical centers, corporate and public hospitals, and regional and district hospitals. Established in 2007, Bora Pharmaceuticals Co., LTD. is based in Taipei City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 14, 2025 | NT$13.55+67.7% vs estimate | NT$4.48B-12.55% vs estimate |
|---|
| Q4 2024 | Mar 5, 2025 | NT$4.95-41.0% vs estimate | NT$5.75B-4.05% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | NT$13.80+67.68% vs estimate | NT$5.62B-6.24% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$167.50-NT$5.00 (-2.9%)
Lotus Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 54.67% below the high.
NT$79.90-NT$0.50 (-0.62%)
TTY Biopharm Company Limited’s quoted price sits in the upper half of its reported 52-week range, 8.16% below the high.
NT$59.70-NT$0.10 (-0.17%)
YungShin Global Holding Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.71% below the high.
NT$28.80-NT$0.15 (-0.52%)
Synmosa Biopharma Corporation’s quoted price sits in the lower half of its reported 52-week range, 8.54% below the high.
NT$56.70-NT$0.20 (-0.35%)
Standard Chem & Pharm Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.36% below the high.
NT$43.50-NT$0.30 (-0.68%)
Orient EuroPharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 12.3% below the high.
NT$55.70+NT$0.80 (+1.46%)
TSH Biopharm Corporation Limited’s quoted price sits in the upper half of its reported 52-week range, 6.07% below the high.
NT$23.20-NT$0.50 (-2.11%)
Excelsior Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.06% below the high.
